

Changes in the Regulatory Environment Surrounding the Asian Region and Responses – Collaboration with PMDA

Worasuda Yoongthong Director of Medicines Regulation Division Thai Food and Drug Administration

August 29th, 2024, Bangkok



Key Measures

- 1. Promote Regulatory Convergence and Harmonization
- 2. Leverage Digital Transformation and Regulatory Innovation
- 3. Enhance Clinical Trial Capabilities and Collaboration
- 4. Capacity Building and Regulatory training
- 5. Accelerate Development of Advanced Therapies
- 6. Focus on Regional Supply Chain Resilience
- 7. Foster Public-Private Partnerships
- 8. Strengthen Pharmacovigilance and Post-Market Surveillance
- 9. Encourage Sustainable and Value-Based Healthcare Models



1. Promote Regulatory Convergence and Harmonization

- Adopt Common Standards
- Mutual Recognition Agreements (MRAs)



2. Leverage Digital Transformation and Regulatory Innovation

- Digital Submissions and Al-Driven Review Processes
- Regulatory Sandboxes for Emerging Technologies



3. Enhance Clinical Trial Capabilities and Collaboration

- Regional Clinical Trial Networks
- Adopt Adaptive Trial Designs



4. Capacity Building and Regulatory Training

- Knowledge Sharing Initiatives
- Regional Centers of Excellence



5. Accelerate Development of Advanced Therapies

- Joint Advanced Therapy Pathways
- Incentivize Biologics and Regenerative Medicine



6. Focus on Regional Supply Chain Resilience

- Strengthen Supply Chain Networks
- Digital Supply Chain Management



7. Foster Public-Private Partnerships

- Collaborative Research Initiatives
- Innovation Incubators



8. Strengthen Pharmacovigilance and Post-Market Surveillance

- Harmonized Regional Pharmacovigilance Systems
- Real-Time Monitoring Technologies



9. Encourage Sustainable and Value-Based Healthcare Models

- Value-Based Pricing Models
- Green Manufacturing Initiatives



Thank you